Market Overview

The China Radiopharmaceuticals Market is experiencing explosive growth as the country invests heavily in nuclear medicine infrastructure and domestic isotope production to meet the rising demand for precision diagnostics and targeted therapies. Radiopharmaceuticals are indispensable tools in modern precision medicine, revolutionizing diagnostic imaging and therapeutic strategies. The China radiopharmaceuticals market is projected to grow from USD 0.58 billion in 2025 to USD 1.27 billion by 2035, at a CAGR of 8.26%. This growth is driven by the increasing incidence of cancer, government initiatives and funding, an aging population, and technological advancements in radiopharmaceuticals. China's radiopharmaceutical market reached $840.96 million in 2024, growing at a CAGR of 12.3%, outpacing the global average. The country has 42 approved radiopharmaceuticals, with 32 more in clinical trials, primarily focused on oncology (44.6%), neurology (18.9%), and cardiology (12.2%).

Current Market Landscape

Oncology is a key application segment, holding the largest share due to the rising incidence of cancer and the increasing adoption of radiopharmaceuticals for diagnostic and therapeutic purposes. Hospitals is a key end-user segment, holding the largest share due to their comprehensive healthcare services and varied patient needs. Diagnostic Radiopharmaceuticals is a key type segment, holding the largest share due to their crucial role in medical imaging and diagnostics. Key players including China Isotope & Radiation Corporation, Shanghai United Imaging Healthcare, Siemens Healthineers, and GE Healthcare are focusing on strategic partnerships, product innovation, and expanding their manufacturing capabilities.

Emerging Trends

A major trend is the rapid development of targeted radioligand therapies for cancer treatment, with Novartis's Pluvicto becoming the first therapy of its kind approved in China in November 2025. The country is racing to build a complete radiopharmaceutical supply chain, with a government blueprint issued in 2021 by eight departments, including the China Atomic Energy Authority. The number of companies in China focusing on nuclear medicine has grown from around 20 to nearly 100 between 2019 and 2024. China achieved a breakthrough in June 2025 when CNNC's Qinshan Nuclear Power Plant started shipping domestically produced lutetium-177, a key isotope for targeted therapies. The development of 68Ga-FAPI tracers for cancer imaging and expansion of 177Lu-based therapies are key areas of innovation.

Future Outlook

The future of the China radiopharmaceuticals market will be defined by domestic innovation and expanded clinical applications. The development of novel radionuclide-drug conjugates and theranostic approaches will transform cancer care. The expansion of PET/CT and nuclear medicine infrastructure will increase patient access to advanced diagnostics. By 2035, China is expected to be a global leader in radiopharmaceutical production and innovation, with a robust domestic supply chain and a thriving ecosystem of biotechnology companies.

Conclusion

The China Radiopharmaceuticals Market is at the forefront of a nuclear medicine revolution, driven by strong government support, rapid technological innovation, and a growing patient population, positioning the country as a global leader in this critical field.

Frequently Asked Questions

Q1: What is a key application segment?
A: Oncology is a key application segment, holding the largest share due to the rising incidence of cancer and the increasing adoption of radiopharmaceuticals for diagnostic and therapeutic purposes.

Q2: What is a key end-user segment?
A: Hospitals is a key end-user segment, holding the largest share due to their comprehensive healthcare services and varied patient needs.

Q3: What are the key trends shaping the market?
A: The development of targeted radioligand therapies and the growth of domestic isotope production are key trends.

#ChinaRadiopharmaceuticals #NuclearMedicine #PrecisionMedicine #CancerTherapy #IsotopeProduction